Back

Lactate cannot replace glucose for maintaining the viability of mouse and human glioma cells

Miller, E. Y.; Duraj, T.; Ta, N. L.; Lee, D. C.; Mukherjee, P.; Shaver, O.; Seyfried, T. N.

2025-06-06 cancer biology
10.1101/2025.06.03.655413 bioRxiv
Show abstract

ObjectivesAerobic lactic acid fermentation (the "Warburg effect") is associated with OxPhos insufficiency and altered energy metabolism in most cancers. Whether lactate is a major fuel in cancer cells remains debated. This study investigated whether lactate could serve as a metabolic fuel in glioma cells and replace glucose to support viability. MethodsA bioluminescence ATP assay and calcein-AM/EthD-III double-staining were used to measure ATP content and viability in mouse (VM-M3, CT-2A) and human (U-87MG) glioma cells differing in cell biology and genetic background. Viability was assessed in thioglycollate-elicited peritoneal macrophages (TPMs) from VM/Dk and C57BL/6J mice, used as syngeneic non-neoplastic controls for VM-M3 and CT-2A gliomas, respectively. Oxygen consumption rate (OCR) was determined using the Resipher system. ResultsLactate alone failed to sustain ATP content and viability in all glioma cell lines. ATP content and viability were lower in cancer cells cultured in glutamine and lactate than in glucose and glutamine. In contrast, lactate alone sustained over 45% viability in both TPM models. Moreover, viability was similar between TPMs cultured in glutamine and lactate and in glucose and glutamine. In human U-87MG, lactate addition under severe glucose restriction increased OCR and viability. A low dose of the glycolysis inhibitor 2-deoxy-D-glucose abolished both increases. ConclusionsOur results suggest non-neoplastic mouse TPMs utilize lactate more effectively than mouse glioma cells. In U-87MG, lactate utilization appears glycolysis-dependent, given its sensitivity to 2-deoxy-D-glucose. In conclusion, our data does not support lactate as a major oxidative fuel for viability in mouse and human glioma cells.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
PLOS ONE
5266 papers in training set
Top 15%
12.8%
2
FEBS Open Bio
31 papers in training set
Top 0.1%
7.3%
3
International Journal of Molecular Sciences
494 papers in training set
Top 0.9%
6.3%
4
Experimental Cell Research
28 papers in training set
Top 0.1%
6.3%
5
Frontiers in Oncology
103 papers in training set
Top 0.9%
4.1%
6
Scientific Reports
3612 papers in training set
Top 26%
4.1%
7
Cancers
213 papers in training set
Top 2%
3.3%
8
Neoplasia
23 papers in training set
Top 0.1%
3.2%
9
Biomolecules
100 papers in training set
Top 0.5%
2.5%
10
Cancer Letters
35 papers in training set
Top 0.4%
2.1%
50% of probability mass above
11
Molecular Oncology
55 papers in training set
Top 0.5%
2.1%
12
Biochemical and Biophysical Research Communications
84 papers in training set
Top 0.8%
1.9%
13
Acta Neuropathologica Communications
89 papers in training set
Top 1%
1.7%
14
BMC Cancer
67 papers in training set
Top 1%
1.7%
15
Cells
249 papers in training set
Top 3%
1.7%
16
Aging
75 papers in training set
Top 1%
1.4%
17
iScience
1154 papers in training set
Top 22%
1.3%
18
Frontiers in Molecular Biosciences
102 papers in training set
Top 1%
1.3%
19
Frontiers in Cell and Developmental Biology
233 papers in training set
Top 3%
1.1%
20
Biochemical Pharmacology
20 papers in training set
Top 0.3%
1.1%
21
International Journal of Cancer
49 papers in training set
Top 1.0%
1.0%
22
Journal of Biological Chemistry
690 papers in training set
Top 8%
1.0%
23
Cancer Research Communications
51 papers in training set
Top 1%
1.0%
24
Life Sciences
27 papers in training set
Top 0.9%
1.0%
25
The FASEB Journal
194 papers in training set
Top 5%
1.0%
26
ASN Neuro
10 papers in training set
Top 0.1%
0.9%
27
Metabolites
53 papers in training set
Top 0.9%
0.9%
28
The FEBS Journal
93 papers in training set
Top 2%
0.9%
29
Nutrients
67 papers in training set
Top 2%
0.9%
30
Cell Communication and Signaling
51 papers in training set
Top 1%
0.9%